Apixaban DOAC selectively inhibits factor Xa.

– Indicated for NVAF patients for prophylaxis from stroke and systemic embolism

– Used for VTE treatment and prophylaxis from VTE

Apixatrack available with 2 concentrations

Apixatrack 5 mg (10 tablets)

Apixatrack 2.5 mg (20 tablets)

Loading